MDI Therapeutics is a pharmaceutical company based in Novi, MI, specializing in the development of novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders. Founded on key enabling technologies from the University of Michigan, MDI's lead program focuses on a first-in-class orally available plasminogen activator inhibitor (PAI-1) inhibitor.
With a team of experienced professionals, including Stephen Benoit as President and CEO, MDI Therapeutics aims to address the unmet medical needs in fibrotic diseases by targeting the pathological processes associated with PAI-1. Their research and development efforts are driven by a deep understanding of the role of PAI-1 in regulating fibrinolysis, wound healing, and various chronic fibrotic diseases.
Generated from the website